Unknown

Dataset Information

0

Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report.

ABSTRACT: Tyrosine kinase inhibitors (TKIs) represent the standard treatment for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. The duration of the response is, however, limited in time owing to the development of resistance mechanisms to both first- and second-generation agents such as MET oncogene amplification. This report describes the successful results obtained with the combination of the third-generation TKI osimertinib with the multitargeted TKI and MET inhibitor crizotinib in a patient with EGFR-mutant NSCLC with emerging MET amplification with a tolerable toxicity profile.

SUBMITTER: Blasi M 

PROVIDER: S-EPMC8077408 | biostudies-literature | 2021 Jan-Apr

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report.

Blasi Miriam M   Kazdal Daniel D   Thomas Michael M   Christopoulos Petros P   Kriegsmann Mark M   Brandt Regine R   Volckmar Anna-Lena AL   Kirchner Martina M   Heußel Claus Peter CP   Stenzinger Albrecht A   Kuon Jonas J  

Case reports in oncology 20210101 1

Tyrosine kinase inhibitors (TKIs) represent the standard treatment for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. The duration of the response is, however, limited in time owing to the development of resistance mechanisms to both first- and second-generation agents such as <i>MET</i> oncogene amplification. This report describes the successful results obtained with the combination of the third-generation TKI osimertinib with the  ...[more]

Similar Datasets

Unknown Osimertinib for EGFR-Mutant NSCLC Patients With Acquired T790M and EGFR Amplification After First-Generation EGFR-TKI Resistance.
| S-EPMC11875782 | biostudies-literature
Unknown MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib.
| S-EPMC7540985 | biostudies-literature
Unknown Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib.
| S-EPMC10682450 | biostudies-literature
Unknown PD-L1 regulates c-MET phosphorylation and contributes to MET-dependent resistance to osimertinib in EGFR-mutant NSCLC.
| S-EPMC12509346 | biostudies-literature
Unknown Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
| S-EPMC6762027 | biostudies-literature
Unknown Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.
| S-EPMC2879581 | biostudies-literature
Unknown Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC.
| S-EPMC10462815 | biostudies-literature
Unknown ACTN4 Gene Amplification and Actinin-4 Protein Expression for Osimertinib Efficacy in EGFR-Mutant NSCLC.
| S-EPMC12666467 | biostudies-literature
Unknown Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation.
| S-EPMC9156817 | biostudies-literature
Unknown Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S.
| S-EPMC6886544 | biostudies-literature